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Introduction 
Life in its simplest form can be divided into two 
dimensions, quantity and quality. The maintenance 
of overall functional capacity and general health of 
patients remains the primary role of medical care. The 
importance of quality of life (QL) is embodied in 
the World Health Organisation's (WHO) definition of 
health as not only the absence of infirmity, but also as 
a state of physical, social and mental well-being. 1 As 
many interventions in vascular surgery are primarily 
aimed at improving quality of life rather than its 
duration, vascular surgeons have come to realise the 
importance of formal QL analysis as an independent 
outcome measures in the evaluation of care. 2 There 
can be no doubt that in health economics, quality of 
life measures are fast becoming the standard means 
of assessing health care interventions, and will become 
increasingly important in resource allocation. 3 There- 
fore the routine incorporation of QL analysis into 
future clinical practice would seem almost mandatory 
in the present climate. The following article will ad- 
dress methods of QL analysis and provide suggestions 
for its application. 
Measuring quality of life 4'5 
The main approaches to QL analysis include: 
Generic analysis. Generic measures address the multi- 
dimensional aspects of life, are designed for use with 
* Please address all corresponence to: Mr I. C. Chetter, Department 
of Vascular and Endovascular Surgery, St. James's and Seacroft 
University Hospitals, Beckett Street, Leeds, LS9 7TF, U.K. 
any population sample or illness group, and thus are 
applicable to a wide range of health problems. The 
majority of generic instruments reflect he WHO defin- 
ition of health by assessing the theoretically or em- 
pirically distinct aspects of health, commonly termed 
domains or dimensions. Domains frequently measured 
by generic instruments include: physical functioning 
(mobility, self care), emotion or mood (anxiety, de- 
pression, vitality), social functioning (social activities, 
contact and isolation), role performance (work, house- 
work), pain, and other commonly performed daily 
activities, e.g. sleep and sexual functioning. These 
generic instruments can be further subdivided into 
those which provide a single global score or "health 
index" and those which provide a number of domain 
scores or "health profile". Some instruments provide 
both. The main advantage of a single index is that it 
can be incorporated into quality adjusted life year 
(QALY) calculations and can thus be used in cost 
effectiveness/utility analyses. This broad approach to 
QL analysis facilitates comparisons between different 
disease groups and different centres; however, re- 
sponsiveness may suffer. 
Disease specific analysis. Disease specific QL analysis 
has been developed to assess symptoms pecific to 
one disease or a narrow range of diseases and/or their 
particular treatments. The International Breast Cancer 
Study Group extended this further to evaluate the 
impact of treatment side effects on QL by analysing 
quality adjusted time without symptoms and toxicity 
(Q-TWiST). 6 Disease specific instruments may improve 
patient acceptability by including only relevant do- 
mains, and thus responsiveness hould also be in- 
creased. However, comparability with other studies 
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not using the same instrument may be a problem and 
benefits in dimensions not studied will be missed. 
Perhaps it may be more fruitful in the case of lower 
limb ischaemia to analyse the impact hat peripheral 
vascular disease specifically imparts on patients' QL. 
Domain specific analysis. This involves the selection of 
relevant specific instruments for each domain, i.e. an 
individual instrument is used to analyse pain (e.g. 
MCGill Pain Questionnaire), mental health (e.g. Hos- 
pital Anxiety and Depression Scale), social functioning 
(e.g. Rand Social Activities Questionnaire) tc. This 
perhaps improves responsiveness but may make com- 
parisons almost impossible, as it is highly unlikely 
that different centres will agree on the appropriateness 
of all instruments. 
Patient orientated analysis. This is a more recent and 
novel approach. These instruments allow patients to 
select the domains of most concern; thus it can be 
argued that they reflect patients' priorities and pref- 
erences, avoid domains unlikely to be influenced by 
a specific disease, and are likely to demonstrate greater 
responsiveness than generic measures. 
Methodological Issues 7 
Reliability. This is the extent o which an instrument 
produces consistent results from the same subjects at 
different times when there exists no evidence of 
change. Test-retest involves the administration of an 
instrument on two separate occasions to the same 
group of subjects. An estimate of reliability is provided 
by the correlation between the separate responses. 
The timing between responses is vital: it must be 
sufficiently long to ensure responses are not re- 
membered, but sufficiently short to ensure any actual 
changes in scores are minimal. Inter-observer re- 
liability assesses the consistency between responses 
when they are administred by different interviewers 
with only a short period of time between interviews. 
Statistical nalysis with Kappa coefficient of agreement 
determines whether differences are due to agreement 
or chance. Internal consistency examines the extent o 
which a number of items assessing the same concept 
correlate. Cronbach's alpha, a statistical test based on 
the mean correlation between items, is often utilised 
to analyse internal reliability. 
Validity. This is the extent o which an instrument is
actually measuring what it reports to measure. Face 
validity simply and informally reflects how well the 
instrument, and its item content, appears to cover 
the desired domain. Construct validity assesses the 
instruments ability to confirm a hypothesis; i.e. those 
with illnesses core significantly worse QL than those 
without. Convergent and divergent validity assess the 
correlation between like and non-like domains. 
Responsiveness or sensitivity to change. This is the in- 
strument's ability to detect changes in health status 
over time. This is one of the most important char- 
acteristics of any QL instrument. Common causes of 
insensitivity include: inclusion of items not relevant 
to a particular disease or patient group, inclusion of 
items which are static or unaffected by intervention, 
the inability to detect improvement (ceiling) or de- 
terioration (floor effects) due to initial maximal or 
minimal scores, and finally some instruments contain 
too few broad categories to register subtle but im- 
portant changes in patients' QL. Effect size has been 
recommended as a method for evaluating re- 
sponsiveness. 
Practicality. The ideal instrument to assess QL should 
be valid, reliable, sufficiently brief to achieve good 
response rates and sufficiently detailed to ensure ad- 
equate responsiveness. It should be simple for patients 
to understand and complete, and for health pro- 
fessionals to administer, score and analyse. Needless 
to say such an instrument does not exist, and indeed 
an instrument which may approach this ideal in one 
particular group of patients may fail to do so in another. 
Therefore, whenever a QL instrument is utilised, it 
is important hat these aspects of QL analysis are 
addressed. 
Applications 8 
Clinical 
Formal health related QL analysis on initial evaluation 
allows the clinician to evaluate the impact of the 
disease on the patient's QL. This may then be compared 
to population orms, and may draw attention to areas 
of impairment which may have otherwise have been 
overlooked or unsuspected. It also provides abaseline 
against which effectiveness of subsequent in- 
terventions can be measured. The severity of im- 
pairment could arguably be utilised to firstly influence 
decisions regarding appropriateness of treatment, and 
secondly to prioritise waiting lists for investigation 
or intervention. It has been demonstrated that the 
correlation between traditional clinical indicators of 
lower limb ischaemia nd QL is not strong; thus on 
an individual patient basis variations in these clinical 
indicators cannot be assumed to impart reciprocal QL 
changes and therefore formal QL analysis would seem 
almost mandatory: 9 Previously unsuspected im- 
pairments or limitations following investigations or 
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interventions may be highlighted by QL analysis at 
appropriate intervals: this again may influence clinical 
decision making. During follow-up, health related QL 
analysis allows the clinician to monitor the natural 
history of the disorder, to assess the impact of treat- 
ment, and may draw attention to otherwise un- 
suspected events or complications and facilitate 
focusing of effort. Given these advantages, why then 
is QL analysis not already routinely used in vascular 
surgical practice? The first problem is that of un- 
familiarity with questionnaires, e.g. how bad is a SF36 
pain score of 66 and how much improvement is meant 
by a subsequent score of 89. This problem is con- 
founded by the multiplicity of measures, and in order 
to promote familiarity perhaps the adoption of a single 
or small number of core measures hould be re- 
commended. We have found the SF36 to be the most 
appropriate commonly used generic instrument for 
use in patients with lower limb ischaemia in terms of 
validity, reliability and responsiveness. I° There are also 
the technical problems of when and how to administer 
QL measures and some standardisation f methods in 
this regard is required. 
Resource allocation 
QL measures which produce a single, global QL index 
can be incorporated into quality adjusted life years 
(QALYs), which combine changes in QL and survival 
to assess benefit. The QALYs gained can then be 
divided by cost and the resulting ratio used to assist 
decision making in resource allocation. QALYs can be 
influential when choosing between alternative treat- 
ment programmes for the same patients (cost ef- 
fectiveness analysis) or more controversially, tochoose 
among programmes targeted at different groups (cost 
utility analysis). The use of QALYs to assist decision 
making regarding resource allocation remains con- 
troversial. Critics have raised ethical, political and 
methodological objections regarding their use, whilst 
supporters have stated that the QALY is intended only 
as an aid to decision making, not a strict recipe and 
highlighted the lack of an alternative utility measure. 
This article does not attempt o resolve the QALY 
dispute but simply highlights areas in which QALYs 
may be used to aid decision making regarding resource 
allocation. Firstly, at the highest level QALYs may 
strengthen the bidding for the overall national health 
budget from the treasury, and secondly may assist in 
setting national priorities under the agenda "The 
Health of the Nation". At a more local level QALYs 
may influence decisions made by  health service 
purchasers, as decisions supported by reference to 
measurable QL improvements are much easier to de- 
fend. Finally, clinical, strategic and organisational de- 
cisions made by health service providers may be 
influenced by QALY data. 
Conclusion 
QL analysis is, quite rightly, here to stay as an in- 
dependent outcome measure in vascular surgery. 
However, many basic methodological questions con- 
cerning instrument validity, reliability, reponsiveness 
and patient acceptability still prevail. Questions uch 
as, "Which is the most appropriate approach to QL 
analysis in vascular patients?", Should instruments be 
patient or interview completed, and does this influence 
responses?" and "What impact does the natural history 
of the disease have on patients QL and how does this 
compare to an age/sex matched population?" all have 
to be answered before QL analysis is included in 
routine clinical practise. 
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